Nanofiltration for Better Energy Storage

"Nanofiltration membranes enhance the efficiency of vanadium redox flow batteries."

Scientists in China have found that nanofiltration membranes could enhance the efficiency of vanadium redox flow batteries (VRBs), making them a more viable tool for large-scale energy storage.

Xianfeng Li from the Chinese Academy of Sciences in Dalian and his team made the membranes, which separate two components in the batteries, from polyacrylonitrile. Pores in the membrane can be adjusted, allowing scientists to have more control over the ions passing from one side of the battery to the other during charge/discharge cycles, improving the battery's performance.

nanofiltration

The random and intermittent nature of renewable wind and solar energy sources can limit the power output quality, says Li, who adds that 'energy storage is the key to solving this problem.' VRBs can store a significant amount of energy. In these batteries, two electrolyte tanks containing species of vanadium in different valance states are separated by an ion exchange membrane. When the battery is charged, the vanadium ions are oxidized or reduced, converting chemical energy into electrical energy.

Ion exchange membranes should prevent the crossover of vanadium ions, while allowing protons to pass through. But the ones most commonly used—perfluorinated polymers, such as Nafion—let vanadium ions through and are expensive to buy, despite showing high proton conductivity and chemical stability. Other low-cost membranes need additional ion-exchange groups, which lower their stability. The difficulty in finding a suitable membrane has limited the commercialization of VRBs, Li explains.

John Varcoe, who develops systems for clean/sustainable energy generation at the University of Surrey, UK, says using nanofiltration membranes in redox flow batteries is 'an exciting new development in the field.' 'The simplicity of the system does not lead to a sacrifice in performance and efficiency,' he adds.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.